Overview

111-In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen

Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to describe the toxicity, biodistribution, pharmacokinetics and tumour uptake of a single infusion of ch806 (tagged with a trace amount of radioactive 111-Indium: 111In-ch806) in patients with advanced tumours expressing the 806 antigen.
Phase:
Phase 1
Details
Lead Sponsor:
Ludwig Institute for Cancer Research